CD74 and intratumoral immune response in breast cancer

Zhi-Qiang Wang; Katy Milne; John R. Webb; Peter H. Watson

doi:10.18632/oncotarget.8610

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CD74 and intratumoral immune response in breast cancer

Zhi-Qiang Wang, Katy Milne, John R. Webb and Peter H. Watson _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:12664-12674. https://doi.org/10.18632/oncotarget.8610

Metrics: PDF 2312 views | HTML 3505 views | ?

Abstract

Zhi-Qiang Wang1, Katy Milne1, John R. Webb1, Peter H. Watson1,2

1Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada

2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence to:

Peter H. Watson, email: [email protected]

Keywords: CD74, MHCII, CD4, CD8, CD68

Received: December 15, 2015 Accepted: March 18, 2016 Published: April 06, 2016

ABSTRACT

CD74 (invariant chain) plays a role in MHC class II antigen presentation. We assessed CD74 and MHCII expression in tumor cells, as well as CD8, CD4, and CD68 tumor infiltrating leucocyte (TIL) density by immunohistochemistry in a cohort of 492 breast cancer patients. CD74 expression was associated with poor prognostic markers including patient age, tumor grade, ER status, non-Luminal A subtypes, and with MHCII expression and higher TIL densities, particularly in the Basal-like subgroup. Univariate analysis showed a favorable prognostic effect of CD74 (Hazard ratio = 0.46, 95% CI = 0.26–0.89, p = 0.022) and for combined CD74/MHCII (Hazard ratio = 0.26, 95% CI = 0.17–0.81, p = 0.014) positive status for overall survival that was only manifested in the Basal-like subgroup. CD74 and MHCII expression is associated with patient survival in Basal-like breast cancer, and the association with TIL may reflect an effective intratumoral immune response.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8610

Publication Alerts

Research Papers:

CD74 and intratumoral immune response in breast cancer

Abstract